Australia's Healius rises on sale of unit Agilex; Jefferies lifts PT

** Shares of Australia's Healius HLS.AX rise as much as 18.1% to A$0.425, their biggest intraday gain since August 20

** Jefferies raises price target to A$0.44 from A$0.41, keeps 'hold' rating

** Healthcare firm agrees to sell its unit Agilex Biolabs to subsidiary of Novotech Health for enterprise value of A$160 million ($112.18 million)

** "Post this sale, we will be watching even closer for solid pathology volume growth in FY27E, which will be critical for margin improvement," Jefferies says

** Brokerage says it now expects Healius' FY27 and FY28 NPAT to be less negative

** Helius expects cash proceeds of A$155 million after costs

** Co says Agilex Biolabs' disposal at a sufficiently attractive price would unlock value for shareholders and support management focus on ongoing growth of Healius' core pathology business

** Stock down 58% YTD

($1 = 1.4263 Australian dollars)